Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.28 Million USD | 20.0% |
| 2022 | 17.74 Million USD | 420.33% |
| 2021 | 3.4 Million USD | 132.34% |
| 2020 | 1.46 Million USD | 117.84% |
| 2019 | 673.7 Thousand USD | 10.32% |
| 2018 | 610.7 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 19.84 Million USD | -6.81% |
| 2024 Q2 | 17.63 Million USD | -11.12% |
| 2023 Q3 | 18.72 Million USD | -6.07% |
| 2023 Q2 | 19.93 Million USD | -6.2% |
| 2023 FY | 21.28 Million USD | 20.0% |
| 2023 Q1 | 21.24 Million USD | 19.76% |
| 2023 Q4 | 21.28 Million USD | 13.72% |
| 2022 Q3 | 12.73 Million USD | 64.56% |
| 2022 Q2 | 7.73 Million USD | 32.12% |
| 2022 FY | 17.74 Million USD | 420.33% |
| 2022 Q1 | 5.85 Million USD | 71.79% |
| 2022 Q4 | 17.74 Million USD | 39.32% |
| 2021 Q1 | 1.69 Million USD | 15.83% |
| 2021 FY | 3.4 Million USD | 132.34% |
| 2021 Q4 | 3.4 Million USD | 136.0% |
| 2021 Q3 | 1.44 Million USD | -7.77% |
| 2021 Q2 | 1.56 Million USD | -7.84% |
| 2020 Q3 | 2.25 Million USD | 26.04% |
| 2020 Q2 | 1.78 Million USD | 101.45% |
| 2020 FY | 1.46 Million USD | 117.84% |
| 2020 Q1 | 886.7 Thousand USD | 31.62% |
| 2020 Q4 | 1.46 Million USD | -34.82% |
| 2019 Q4 | 673.7 Thousand USD | 0.0% |
| 2019 FY | 673.7 Thousand USD | 10.32% |
| 2018 FY | 610.7 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -341.243% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -796.035% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 45.308% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 83.949% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -666.096% |
| Better Therapeutics, Inc. | 23.84 Million USD | 10.705% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -156.999% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -113.449% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 19.17% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 33.015% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 69.338% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -167.945% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 55.749% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 86.468% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -507.247% |
| Molecular Templates, Inc. | 31.17 Million USD | 31.7% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -70.115% |
| NexImmune, Inc. | 5.08 Million USD | -318.742% |
| Orgenesis Inc. | 35.53 Million USD | 40.088% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -28.935% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -7891.247% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -827.526% |
| Scopus BioPharma Inc. | 7.45 Million USD | -185.599% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 95.695% |
| Statera Biopharma, Inc. | 22.67 Million USD | 6.115% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -95.069% |
| Trevena, Inc. | 48.26 Million USD | 55.887% |
| Vaxxinity, Inc. | 30.94 Million USD | 31.199% |
| Vaccinex, Inc. | 5.94 Million USD | -258.294% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -981.614% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 44.519% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -670.934% |